Serrapeptase is a proteolytic enzyme, meaning it breaks down proteins, and it has been studied primarily for reducing inflammation, swelling, and pain after injury or surgery. Originally isolated from bacteria living in the gut of silkworms, it is now produced through fermentation and sold widely as a dietary supplement. The evidence behind it is genuinely interesting in some areas and genuinely thin in others, and the gap between what supplement marketing promises and what clinical trials have actually shown is worth understanding before you spend money on it.
Where Serrapeptase Comes From and How It Works
The enzyme is produced by Serratia marcescens, a bacterium that silkworms carry in their intestines. In nature, the enzyme helps the silkworm dissolve its cocoon. Commercially, it is manufactured through bacterial fermentation rather than harvested from insects. Once purified, it is formulated into supplements, usually as enteric-coated tablets or capsules designed to survive stomach acid and release in the small intestine.
Its biological activity stems from its ability to break down certain proteins. Researchers have attributed anti-inflammatory, analgesic, anti-edema, and fibrinolytic properties to it, along with the ability to disrupt bacterial biofilms.1PubMed Central. Serratiopeptidase: Insights into the therapeutic applications The fibrinolytic piece means it can help break down fibrin, a protein involved in blood clotting and scar tissue. The anti-edema effect, its ability to reduce fluid accumulation in swollen tissues, is probably the most consistently observed benefit across the existing studies.
Swelling and Recovery After Surgery
The strongest cluster of clinical evidence for serrapeptase involves dental surgery, specifically the swelling that follows extraction of impacted wisdom teeth. This is a convenient model for researchers because the surgery is common, the inflammation is predictable, and outcomes like cheek swelling and jaw stiffness are straightforward to measure.
In one controlled trial, patients who took serrapeptase after wisdom tooth extraction experienced significantly less cheek swelling and lower pain intensity on the second, third, and seventh days after surgery compared to the control group. The enzyme did not, however, improve jaw opening (trismus) in that particular study.2PubMed. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars A systematic review and meta-analysis that pooled results across multiple trials came to a slightly different conclusion: it found that serrapeptase actually improved trismus better than corticosteroids, though swelling reduction was not significantly different between the two.3PubMed Central. Role of Serratiopeptidase After Surgical Removal of Impacted Molar: A Systematic Review and Meta-analysis
The takeaway from the dental surgery literature is that serrapeptase does seem to help with post-operative swelling and possibly jaw stiffness, but the size of the effect and exactly which symptoms it helps with most varies across studies. It is not dramatically better than standard anti-inflammatory drugs for this purpose, but it appears to offer a measurable benefit on top of baseline care.
Pain and Inflammation Beyond the Dentist’s Chair
Outside of dental surgery, the pain-relief picture gets murkier. A study on ankle sprains found that serrapeptase reduced joint edema (swelling) more effectively than paracetamol on the third and tenth days after injury, but pain management was not significantly different between the two groups.4PubMed Central. Efficacy and safety of serrapeptase on ankle sprain cases: A single center prospective comparative study That pattern, better swelling reduction than pain reduction, shows up repeatedly and suggests the enzyme’s main talent is managing edema rather than blocking pain signals directly.
A study on knee osteoarthritis tested whether adding serrapeptase to diclofenac (a common anti-inflammatory drug) would boost its effectiveness. It did not. The combination was no better than diclofenac alone for either pain or inflammation.5International Journal of Research in Pharmaceutical Sciences. The Comparison of Anti-inflammatory and Analgesic Effect of Diclofenac Alone with Combined Treatment with Diclofenac and Serratiopeptidase in Patients having Osteoarthritis of Knee Joint This is a meaningful negative result because it suggests that for chronic inflammatory conditions, serrapeptase may not add much to conventional treatment. The acute, localized swelling after a surgery or injury may simply be a different problem than the chronic, systemic inflammation driving osteoarthritis.
Respiratory and Sinus Effects
One of the more popular claims in supplement marketing is that serrapeptase “thins mucus” and helps with sinus congestion, chronic bronchitis, or other respiratory issues. There is a kernel of truth here, though the evidence is limited. A clinical study measuring the physical properties of nasal mucus found that after four weeks of oral serrapeptase, the viscosity of nasal mucus was significantly lower. The mucus became thinner and presumably easier to clear. The enzyme did not change the elasticity of the mucus, just how thick and resistant to flow it was.6PubMed. The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus
That study is from the late 1980s, and while the finding is real, it was a small trial and has not been robustly replicated with modern methodology. If you have thick, stubborn sinus congestion and you are curious about serrapeptase, this is the finding that would be relevant to you, but keep your expectations modest. No large trial has demonstrated that it meaningfully improves symptoms like nasal obstruction or sinus pressure in a way that competes with standard decongestants or saline irrigation.
Biofilm Disruption and Antibiotic Resistance
Perhaps the most scientifically exciting area of serrapeptase research right now has nothing to do with supplements. Researchers are investigating its ability to break apart bacterial biofilms, the slimy, protective communities that bacteria form on surfaces like medical implants, wounds, and tissues. Biofilms are a major reason certain infections resist antibiotic treatment: the bacteria hunker down inside a protein-and-sugar matrix that drugs struggle to penetrate.
Lab studies have shown that serrapeptase can dramatically reduce biofilm formation. Against E. coli, it inhibited biofilm in a dose-dependent manner and reduced established biofilm viability by about 92% at higher concentrations. The enzyme appeared to work by degrading structural components of the biofilm, particularly curli fibers, which bacteria use to stick to surfaces.7PubMed Central. Serrapeptase Eliminates Escherichia coli Biofilms by Targeting Curli Fibers, Lipopolysaccharides, and Phosphate Metabolism Against Staphylococcus aureus, including methicillin-resistant strains (MRSA), serrapeptase inhibited biofilm formation by up to 88% for susceptible strains and 83% for MRSA.8PubMed Central. Serrapeptase impairs biofilm, wall, and phospho-homeostasis of resistant and susceptible Staphylococcus aureus
These are in vitro results, meaning they happened in lab dishes, not inside living patients. Translating a lab finding into a real clinical therapy is a long road, and you should not take serrapeptase supplements expecting them to fight an active MRSA infection. But the research suggests a genuine mechanism that could eventually inform new strategies for treating biofilm-associated infections, potentially by using serrapeptase alongside antibiotics to strip away the protective biofilm layer and let the drugs reach the bacteria.
Side Effects and Safety Concerns
Serrapeptase is generally considered well-tolerated at typical supplement doses, but “generally well-tolerated” does not mean risk-free. The most commonly reported side effects are gastrointestinal: nausea, stomach discomfort, and diarrhea. These tend to be mild and dose-related.
Rarer but more serious adverse events have been documented. A case report described a 69-year-old man who developed drug-induced pneumonitis after taking serrapeptase for 16 days for a common cold. He developed fever, dry cough, and difficulty breathing, and his chest X-ray showed diffuse abnormalities in both lungs. A lung biopsy confirmed interstitial pneumonia. His symptoms and imaging findings improved markedly once serrapeptase was stopped, and the clinical timeline strongly pointed to the enzyme as the cause.9PubMed. A case of pneumonitis due to serrapeptase This is a single case report, not a common outcome, but it is worth knowing about, especially if you develop unexplained respiratory symptoms while taking the supplement.
Because serrapeptase has fibrinolytic properties (it can help break down fibrin involved in clotting), there is a theoretical concern about increased bleeding risk. If you take blood thinners like warfarin, aspirin, or newer anticoagulants, or if you have a bleeding disorder, this interaction matters. The evidence for clinically significant bleeding events from serrapeptase alone is thin, but the biological mechanism is plausible enough that most clinicians would advise caution. You should also stop taking it before any scheduled surgery.
The Evidence Quality Problem
This is where the story gets honest. A systematic review that assessed the overall body of clinical evidence for serrapeptase as an anti-inflammatory and analgesic agent concluded that the supporting studies suffer from poor methodology. The review noted that most trials were small, often only placebo-controlled, and that some did not even specify the dose or duration of treatment. Outcome definitions were unclear in several studies, and data on safety and tolerability were largely missing.10PubMed. Serratiopeptidase: a systematic review of the existing evidence
This does not mean serrapeptase does nothing. It means we cannot be confident about how much it does, for whom, at what dose, or for how long. Many of the positive findings come from trials with fewer than 100 participants, no blinding, or no active comparator. When a systematic review calls the entire evidence base methodologically poor, that is a significant red flag, not because the enzyme is necessarily ineffective, but because we genuinely do not know its true effect size with any precision. Supplement companies can cherry-pick the positive small trials and present them as proof. The full picture is less impressive.
Absorption Challenges and Why Formulation Matters
Like most protein-based molecules taken by mouth, serrapeptase faces a hostile environment in the stomach. Gastric acid and digestive enzymes can destroy it before it reaches the small intestine where absorption occurs. This is why nearly all commercial serrapeptase supplements use enteric coating, a polymer shell that resists stomach acid and dissolves only at the higher pH of the small intestine.
Research into enteric-coated formulations has shown that the coating effectively prevents serrapeptase release in acidic environments. One study developing improved tablets found that enteric-coated versions restricted enzyme release at stomach pH but released the drug effectively at intestinal pH, outperforming some marketed formulations by a meaningful margin.11PubMed Central. Formulation and development of Serratiopeptidase enteric coated tablets and analytical method validation by UV Spectroscopy The practical implication for consumers is that the quality of the enteric coating varies between products, and a cheap supplement with a poor coating may deliver very little active enzyme to where it needs to go. If you decide to try serrapeptase, taking it on an empty stomach (as most products recommend) helps because food can alter stomach pH and interfere with the coating’s dissolution profile.
How It Compares to Bromelain
Bromelain, a proteolytic enzyme derived from pineapple stems, is the supplement most often compared to serrapeptase. Both are marketed for inflammation and post-surgical recovery, and both have a similar mechanism of action: breaking down proteins involved in the inflammatory response. A head-to-head study after wisdom tooth surgery found that bromelain (combined with diclofenac) was more effective at controlling post-operative pain and swelling than serrapeptase (also combined with diclofenac), though neither enzyme showed a clear advantage for trismus.12Journal of Evolution of Medical and Dental Sciences. Comparison of Efficacy of Oral Bromelain and Serratiopeptidase for the Control of Postoperative Sequelae Following Third Molar Surgery – A Comparative Study
One comparison study is not definitive, but it is worth noting because serrapeptase is often marketed as the superior enzyme. The truth is that both have limited clinical evidence, and neither has been validated in large, well-designed trials for most of the conditions supplement companies claim they treat. Bromelain has a somewhat larger body of published research overall, but the quality issues that plague serrapeptase trials apply to much of the bromelain literature as well.
Experimental Research on Cancer and Drug Delivery
Some early-stage laboratory research has explored serrapeptase in contexts far removed from its traditional supplement uses. One area is cancer research, where serrapeptase has been investigated not as a standalone treatment but as a drug delivery vehicle. Researchers created nanoparticles using serrapeptase as a carrier for curcumin (the active compound in turmeric) and tested them against cervical and breast cancer cell lines. The nanoparticles showed anti-cancer activity in lab tests, including cytotoxicity, DNA damage, and shifts in inflammatory signaling. The researchers noted that serrapeptase shares structural similarity with certain matrix metalloproteinases, a class of enzymes involved in tumor biology, and speculated this could contribute to a synergistic anti-cancer effect.13PubMed. Co-delivery of curcumin and serratiopeptidase in HeLa and MCF-7 cells through nanoparticles show improved anti-cancer activity
This is pure bench science. No one should take serrapeptase hoping to treat or prevent cancer. But it illustrates that the enzyme has properties beyond simple inflammation reduction, and that its ability to interact with proteins and biological membranes makes it interesting to researchers working on drug delivery systems. Whether any of this translates to human therapies remains to be seen, likely years or decades from now.
Who Should Probably Skip It
Certain groups should exercise real caution with serrapeptase. People on anticoagulant or antiplatelet medications face a plausible bleeding risk due to the enzyme’s fibrinolytic activity. Anyone scheduled for surgery should stop taking it at least two weeks beforehand for the same reason. Pregnant and breastfeeding women have essentially no safety data to rely on. People with liver or kidney disease have no pharmacokinetic data specific to their situation. And anyone with a history of allergic reactions to proteolytic enzymes should avoid it entirely.
Because serrapeptase is regulated as a dietary supplement in the United States rather than as a drug, it does not undergo the same pre-market safety and efficacy review that pharmaceuticals do. The dose listed on the label may not reflect what is actually in the product, and quality control varies widely between manufacturers. If you do choose to use it, selecting a product from a company that submits to third-party testing (USP, NSF, or ConsumerLab verification) reduces the risk of getting a product that contains less enzyme than advertised, or one with contaminants.
Anticoagulant Properties and Clotting
The fibrinolytic activity of serrapeptase, mentioned earlier in the context of bleeding risk, has also attracted research interest as a potential mild anticoagulant. An in vitro study testing several natural remedies on bovine plasma found that the tested substances extended average clotting time by between 4% and 28% depending on dosage, with higher doses producing stronger effects. Combining two remedies yielded better anticoagulant results than either alone.14PubMed Central. Evaluating Effectiveness of Select Natural Remedies for their Anticoagulating Properties on Bovine Plasma: An In Vitro Study Again, this is lab work on animal plasma, not a clinical trial in humans. But it reinforces that serrapeptase does have real biological activity related to clotting, and that this is not just a theoretical concern for people who are already on blood thinners.
Some people in the supplement community take serrapeptase specifically hoping to reduce blood clots or improve circulation. The evidence does not support that use in any robust way. A modest extension of clotting time in a test tube does not translate to “dissolves dangerous blood clots in your arteries.” If you have a clotting disorder or cardiovascular disease, pharmaceutical anticoagulants with decades of clinical trial data behind them are the appropriate treatment, not an enzyme supplement with in vitro findings and no relevant human outcome data.